Leave Your Message
ADT1012-Adalimumab Biosimilar-Anti-TNF alpha mAb-Research Grade
Antibody

ADT1012-Adalimumab Biosimilar-Anti-TNF alpha mAb-Research Grade

  • Catalog Number ADT1012
  • Host CHO Cells
  • Target TNF alpha/TNFA/TNFSF2
  • Species Human
  • Application FC, IP, ELISA, Neut, Functional assay

TNFR 2 is a type I transmembrane glycoprotein that plays a vital role in regulating the immune system. It consists of approximately 439 to 461 amino acids and is associated with various inflammatory and autoimmune diseases. On the other hand, adalimumab is a well-established anti-rheumatic drug and monoclonal antibody that targets and inactivates tumor necrosis factor-α, a key driver of inflammation in diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Through phage display antibody library construction and screening technologies, Alpha Lifetech ensures the rapid discovery of high-affinity blocking antibodies.

Products Categories
Featured Products
recommended service
quick links
Contact Us

Product Background

Adalimumab binds with specificity to tumor necrosis factor-alpha and Inhibits its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface tumor necrosis factor-expressing cells in vitro when in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin. TNF is a naturally occurring cytokine that plays a role in normal inflammatory and immune responses. Increased levels of TNF are found in the joint synovial fluid of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients, and play an imperative role in pathologic inflammation and joint destruction that are major complications of these diseases. Increased levels of TNF are also measured in psoriasis plaques. In plaque psoriasis, treatment with adalimumab may decrease the epidermal thickness and inflammatory cell infiltration. The relationship between these pharmacodynamics and the mechanism by which adalimumab achieves its clinical effects is not known. Additionally, adalimumab alters biological responses that are induced/regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration during inflammation.

Product Specification

Catalog Number

ADT1012

Product Name

Recombinant Human Biotinylated CD28 Protein, Fc Tag, Avi Tag

Alias

D2E7, Ig gamma-1 chain C region

Isotype

IgG1 Kappa

Clonity

Monoclonal

Alternate Names

tnf alpha, tnf alpha gene, tnf alpha pathway, mouse tnf alpha, anti tnf alpha, tnf-alpha protein, tnf alpha monoclonal antibody, human tnf alpha, anti-tnf-alpha therapy, tnfa gene

Official Symbol

TNF alpha/TNFA/TNFSF2

Species

Human

Expression Host

CHO Cells

Research Area

Immunology

Product Description

Adalimumab is a disease-modifying antirheumatic drug and monoclonal antibody that works by inactivating tumor necrosis factor-alpha.

Mechanism of Action

Adalimumab binds with specificity to tumor necrosis factor-alpha (TNF-alpha) and inhibits its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface tumor necrosis factor expressing cells in vitro when in the presence of complement.

Metabolism

Most likely removed by opsonization via the reticuloendothelial system.

Gene ID

7124

Size

1mg,5mg

CAS Number

331731-18-1

Molecular Weight

144KDa

Chemical Formula

C6428H9912N1694O1987S46

Application

FC, IP, ELISA, Neut, Functional assay

Purity

>95% as determined by SDS-PAGE

Concentration

Batch dependent

Buffer

Supplied in PBS, PH7.5

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only. 

Reactivity

Human

Reference

1.Nuber-Champier A, et al. Psychoneuroendocrinology, 2023 Jul. PMID 37104966
2.Sudershan A, et al. BMC Neurol, 2023 Apr 21. PMID 37085790
3.Lücke J, et al. Front Immunol, 2023. PMID 37063909

 

FAQ

Leave Your Message